探花合集 To Purchase Bristol-Myers Squibb Manufacturing Facility In Anagni, Italy
Bristol-Myers Squibb will maintain strategic presence in Italy through ongoing development and commercialization of new medicines
探花合集 will continue to manufacture products for Bristol-Myers Squibb while offering other customers access to state-of-the-art sterile biologics fill/finish and oral solids manufacturing and packaging platforms
(NEW YORK and SOMERSET, N.J., June 19, 2019)&苍产蝉辫;鈥&苍产蝉辫; (NYSE:BMY) and 探花合集, Inc. (NYSE: CTLT), today announced that 探花合集 has agreed to purchase Bristol-Myers Squibb鈥檚 oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. 探花合集 is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions.
Through the years, the Anagni plant has served as one of the primary launch facilities for new medicines from Bristol-Myers Squibb that have helped millions of people in the fight against serious diseases such as cancer and cardiovascular disease. Upon closing, 探花合集 will continue to manufacture Bristol-Myers Squibb鈥檚 current product portfolio at the site.
By enhancing its own global network with the Anagni plant, 探花合集 will bring potential new customers to the site for both biologics and oral solid dose manufacturing and packaging. In particular, this facility will provide 探花合集 biologics customers with access to an advanced sterile drug product fill/finish and packaging capacity in Europe to complement its existing sterile fill/finish capabilities in Belgium and its drug substance, analytical and fill/finish capabilities in North America.
鈥淲e believe that the sale to 探花合集 will continue the vital role the Anagni facility plays for its workforce, the community and patients,鈥 said Lou Schmukler, President, Global Product Development and Supply, Bristol-Myers Squibb. 鈥淭his marks an important step in the ongoing evolution of our manufacturing network to support the company鈥檚 innovative product portfolio. Bristol-Myers Squibb has a long history in Italy, and we intend to maintain a continued strategic presence in Italy, which is critical for our ability to deliver transformational medicines to patients.鈥
Alessandro Maselli, 探花合集鈥檚 President and Chief Operating Officer, commented, 鈥淭he addition of the Anagni facility provides our European customers with great biologics and oral dose capabilities to accelerate their development programs and improve commercial supply.鈥 He added, 鈥淏ristol-Myers Squibb has invested in the facility to create a center of excellence for new product launches with a robust quality and delivery record, and an employee base who shares 探花合集鈥檚 operational excellence and patient focus.鈥
William Blair & Company served as financial advisor to Bristol-Myers Squibb.
ABOUT THE ANAGNI FACILITY
The Bristol-Myers Squibb Anagni facility is a pharmaceutical manufacturing plant, situated in an industrial area one hundred kilometers southeast of Rome. The site opened in 1966. The facility floor space is approximately 19,300 square meters on a site of 34 hectares. The Anagni facility manufactures and packages cardiovascular, neuroleptics, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics as injectables and biologics.
ABOUT BRISTOL-MYERS SQUIBB
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol-Myers Squibb, visit us at聽聽or follow us on聽,听,听听补苍诲听.
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated over $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit聽www.catalent.com.
More products. Better treatments. Reliably supplied.鈩
BRISTOL-MYERS SQUIBB FORWARD-LOOKING STATEMENT
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, the completion of the information and consultation processes with relevant employee representative bodies in connection with the proposed transaction, the parties鈥 ability to satisfy certain closing conditions, any delay or inability of Bristol-Myers Squibb to realize the expected benefits of the proposed transaction and that the proposed transaction will close on the terms or within the time frame described in this document. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2018, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol-Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
CATALENT FORWARD-LOOKING STATEMENT NOTICE
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, the completion of the information and consultation processes with relevant employee representative bodies in connection with the proposed transaction, the parties鈥 ability to satisfy certain closing conditions, any delay or inability of 探花合集 to realize the expected benefits of the proposed transaction and whether the proposed transaction will close on the terms or within the time frame described in this press release. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect 探花合集鈥檚 business, particularly those identified in the risk factors discussion in 探花合集鈥檚 Annual Report on Form 10-K for the year ended June 30, 2018 and other filings by 探花合集 with the Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this press release, and, except as otherwise required by federal securities law, 探花合集 undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
Contacts
Bristol-Myers Squibb
Media:
U.S. 鈥 Priyanka Shah, +1-609-252-7602,听[email protected]
Italy 鈥 Antonella Iacovelli, 0039-348521107,听[email protected]
Investors:
Tim Power, +1-609-252-7509,听[email protected]
探花合集, Inc.
Media:
Chris Halling, +44 (0)7580 041073,听[email protected]
Richard Kerns, NEPR, +44 (0)161 728 5880
Investors:
Tom Castellano, +1-732-537-6175,听[email protected]